Multiple Myeloma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Multiple myeloma (MM) is a hematologic malignancy characterized by the uncontrolled proliferation of clonal plasma cells in the bone marrow, which secrete significant quantities of non-functional proteins and immunoglobulins. Despite notable therapeutic advancements over many years, MM remains largely incurable. These hyperproliferative differentiated B-lymphocytes can produce various types of immunoglobulins (Ig), with IgG and IgA being the most common and IgD to a lesser extent. Typically, these abnormal plasma cells primarily grow within the bone marrow, with only a small fraction of patients initially showing extramedullary disease. Most patients experience relapses during treatment, progress to a refractory state, and cease to respond to therapy within 60 days of their last treatment: a grim prognosis and a high likelihood of relapse mark this. Additionally, with each subsequent relapse, patients endure progressively shorter periods of progression-free survival (PFS). For instance, PFS for first-line patients is around 18 months, but by the fourth line of therapy, it dwindles to a mere 4.7 months. The primary objective in treating relapsed MM is to alleviate disease symptoms and thwart the emergence of CRAB symptoms, defined as elevated calcium levels (>11.5 mg/dL), increased creatinine levels (>2 mg/dL), low hemoglobin levels (<10 g/dL or >2 points below the lower normal limit), and the development of new bone lesions. Managing relapsed and refractory MM involves a multifaceted treatment approach, which includes a standard combination of proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies. Additionally, treatment may incorporate histone deacetylase inhibitors and alkylating agents.

 

Thelansis’s “Multiple Myeloma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Multiple Myeloma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Multiple Myeloma across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Multiple Myeloma Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Multiple Myeloma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Multiple Myeloma, Multiple Myeloma market outlook, Multiple Myeloma competitive landscape, Multiple Myeloma market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)